A near-infrared phthalocyanine dye-labeled agent for integrin αvβ6-targeted theranostics of pancreatic cancer

Biomaterials

Volumn 53, Issue , 2015, Pages 229-238

  Gao, Duo ^a   Gao, Liquan ^a   Zhang, Chenran ^a   Liu, Hao ^a   Jia, Bing ^a   Zhu, Zhaohui ^b   Wang, Fan ^a,c   Liu, Zhaofei ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c INSTITUTE OF BIOPHYSICS   (China)

Author keywords

Image guided surgery; Intraoperative imaging; Molecular imaging; Molecular probe; Photodynamic therapy

Indexed keywords

BINDING ENERGY; DIAGNOSIS; DYES; GEOMETRICAL OPTICS; INFRARED DEVICES; MOLECULAR IMAGING; OPTICAL IMAGE STORAGE; PHOTODYNAMIC THERAPY; POSITRON EMISSION TOMOGRAPHY; PROTEINS; SURGERY; THERANOSTICS;

FLUORESCENCE STAINING; IMAGE GUIDED SURGERY; INTRA-OPERATIVE IMAGING; MOLECULAR PROBES; PANCREATIC CANCER XENOGRAFTS; PHTHALOCYANINE DYES; POSITRON EMISSION TOMOGRAPHY (PET); THERANOSTIC AGENTS;

DISEASES;

ALPHAVBETA6 INTEGRIN; PHTHALOCYANINE; COLORING AGENT; INDOLE DERIVATIVE; INTEGRIN; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ARTICLE; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; EX VIVO STUDY; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; IN VIVO STUDY; MOLECULAR IMAGING; MOUSE; NONHUMAN; PANCREAS CANCER; PHOTODYNAMIC THERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; MALE; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; THERANOSTIC NANOMEDICINE; XENOGRAFT;

ANIMALIA;

ANIMALS; ANTIGENS, NEOPLASM; COLORING AGENTS; HETEROGRAFTS; HUMANS; INDOLES; INTEGRINS; MALE; MICE; MICE, INBRED BALB C; PANCREATIC NEOPLASMS; THERANOSTIC NANOMEDICINE;

EID: 84927934867     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.02.093     Document Type: Article

References (35)

1. Vincent A., Herman J., Schulick R., Hruban R.H., Goggins M. Pancreatic cancer. Lancet 2011, 378:607-620.
2. Stathis A., Moore M.J. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010, 7:163-172.
3. Hidalgo M. Pancreatic cancer. NEngl J Med 2010, 362:1605-1617.
4. van Dam G.M., Themelis G., Crane L.M., Harlaar N.J., Pleijhuis R.G., Kelder W., et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nat Med 2011, 17:1315-1319.
5. Weissleder R., Ntziachristos V. Shedding light onto live molecular targets. Nat Med 2003, 9:123-128.
6. Ntziachristos V., Bremer C., Weissleder R. Fluorescence imaging with near-infrared light: new technological advances that enable invivo molecular imaging. Eur Radiol 2003, 13:195-208.
7. Yuan A., Wu J., Tang X., Zhao L., Xu F., Hu Y. Application of near-infrared dyes for tumor imaging, photothermal, and photodynamic therapies. JPharm Sci 2013, 102:6-28.
8. Agostinis P., Berg K., Cengel K.A., Foster T.H., Girotti A.W., Gollnick S.O., et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin 2011, 61:250-281.
9. Cheng L., Wang C., Feng L., Yang K., Liu Z. Functional nanomaterials for phototherapies of cancer. Chem Rev 2014, 114:10869-10939.
10. Triesscheijn M., Baas P., Schellens J.H., Stewart F.A. Photodynamic therapy in oncology. Oncologist 2006, 11:1034-1044.
11. Mitsunaga M., Ogawa M., Kosaka N., Rosenblum L.T., Choyke P.L., Kobayashi H. Cancer cell-selective invivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med 2011, 17:1685-1691.
12. Nakajima T., Sano K., Choyke P.L., Kobayashi H. Improving the efficacy of Photoimmunotherapy (PIT) using a cocktail of antibody conjugates in a multiple antigen tumor model. Theranostics 2013, 3:357-365.
13. 18F-FDG PET. JNucl Med 2013, 54:770-775.
14. Wu A.M., Olafsen T. Antibodies for molecular imaging of cancer. Cancer J 2008, 14:191-197.
15. Liu Z., Liu H., Ma T., Sun X., Shi J., Jia B., et al. Integrin alphavbeta6-targeted SPECT imaging for pancreatic cancer detection. JNucl Med 2014, 55:989-994.
16. Bandyopadhyay A., Raghavan S. Defining the role of integrin alphavbeta6 in cancer. Curr Drug Targets 2009, 10:645-652.
17. Liu H., Wu Y., Wang F., Liu Z. Molecular imaging of integrin alphavbeta6 expression in living subjects. Am J Nucl Med Mol Imaging 2014, 4:333-345.
18. Oyama T., Sykes K.F., Samli K.N., Minna J.D., Johnston S.A., Brown K.C. Isolation of lung tumor specific peptides from a random peptide library: generation of diagnostic and cell-targeting reagents. Cancer Lett 2003, 202:219-230.
19. Liu Z., Sun X., Liu H., Ma T., Shi J., Jia B., et al. Early assessment of tumor response to gefitinib treatment by noninvasive optical imaging of tumor vascular endothelial growth factor expression in animal models. JNucl Med 2014, 55:818-823.
20. Sun X., Ma T., Liu H., Yu X., Wu Y., Shi J., et al. Longitudinal monitoring of tumor antiangiogenic therapy with near-infrared fluorophore-labeled agents targeted to integrin alphavbeta3 and vascular endothelial growth factor. Eur J Nucl Med Mol Imaging 2014, 41:1428-1439.
21. Liu Z., Yu Z., He W., Ma S., Sun L., Wang F. In-vitro internalization and in-vivo tumor uptake of anti-EGFR monoclonal antibody LA22 in A549 lung cancer cells and animal model. Cancer Biother Radiopharm 2009, 24:15-24.
22. 99mTc-labeled RGD-BBN peptide for small-animal SPECT/CT of lung carcinoma. Mol Pharmacol 2012, 9:1409-1417.
23. Zhu X.D., Zhang J.B., Zhuang P.Y., Zhu H.G., Zhang W., Xiong Y.Q., et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. JClin Oncol 2008, 26:2707-2716.
24. Elayadi A.N., Samli K.N., Prudkin L., Liu Y.H., Bian A., Xie X.J., et al. Apeptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res 2007, 67:5889-5895.
25. Ersahin D., Doddamane I., Cheng D. Targeted radionuclide therapy. Cancers - Basel 2011, 3:3838-3855.
26. Singh P., Srinivasan R., Wig J.D. Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment. Pancreas 2011, 40:644-652.
27. Sipos B., Hahn D., Carceller A., Piulats J., Hedderich J., Kalthoff H., et al. Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas invivo and invitro. Histopathology 2004, 45:226-236.
28. Guo M., Mao H., Li Y., Zhu A., He H., Yang H., et al. Dual imaging-guided photothermal/photodynamic therapy using micelles. Biomaterials 2014, 35:4656-4666.
29. Haedicke K., Grafe S., Lehmann F., Hilger I. Multiplexed invivo fluorescence optical imaging of the therapeutic efficacy of photodynamic therapy. Biomaterials 2013, 34:10075-10083.
30. Rong P., Yang K., Srivastan A., Kiesewetter D.O., Yue X., Wang F., et al. Photosensitizer loaded nano-graphene for multimodality imaging guided tumor photodynamic therapy. Theranostics 2014, 4:229-239.
31. Mitsunaga M., Nakajima T., Sano K., Choyke P.L., Kobayashi H. Near-infrared theranostic photoimmunotherapy (PIT): repeated exposure of light enhances the effect of immunoconjugate. Bioconj Chem 2012, 23:604-609.
32. Dolmans D.E., Fukumura D., Jain R.K. Photodynamic therapy for cancer. Nat Rev Cancer 2003, 3:380-387.
33. Yoo J.O., Ha K.S. New insights into the mechanisms for photodynamic therapy-induced cancer cell death. Int Rev Cell Mol Biol 2012, 295:139-174.
34. Shirasu N., Yamada H., Shibaguchi H., Kuroki M., Kuroki M. Potent and specific antitumor effect of CEA-targeted photoimmunotherapy. Int J Cancer 2014, 135:2697-2710.
35. Maeda H., Fang J., Inutsuka T., Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol 2003, 3:319-328.